SUPPLEMENT

Original document: COVID-19 is associated with higher risk of venous thrombosis, but not arterial thrombosis, compared with influenza: Insights from a large US cohort

Methods - Additional Details

Since the vast majority of strokes, MIs, and PEs require inpatient treatment, the identification of these endpoints were restricted to inpatient settings to maximize the accuracy of data capture. Inpatient diagnoses were identified as those which were attached to a claim which originated from an inpatient hospital (CMS place of service 21)[1]. However, because a significant percentage of acute DVTs do not require inpatient hospitalization [2], the identification of acute DVT was expanded to the emergency department setting (CMS place of service 23) as well as the inpatient setting. The identification of secondary endpoints (angina, transient ischemic attack, peripheral arterial disease, amputation, coronary angioplasty, coronary artery bypass grafting, venous thrombosis of devices, implants, or grafts) were similarly restricted to ICD codes attached to claims which originated from either an inpatient hospital or emergency room (CMS place of service 21 or 23) [1].

COVID-19 ICD diagnosis codes and LOINC codes for SARS-CoV-2 molecular tests were sourced from the Sentinel Initiative. SARS-CoV-2 antigen tests have been shown to have lower sensitivities and specificities than molecular tests, and were not considered. April 1, 2020 served as the study start date, as that is the date when the ICD code for COVID-19 (U07.1) was released by the CDC; before this, testing was also not widespread.

The baseline period was defined as the 365 days prior to the index date; individuals were only excluded if they have fewer than two encounters in EHR data AND fewer than two claims in insurance claims data within the baseline period (inclusive of the index date). Pediatric patients (under 18 years of age at their index date) were excluded, as the effects of COVID-19 are less pronounced in this population. Patients with no claims information after the index date were excluded to avoid mistakenly presuming patients were healthy after the index date because they have no claims data, when in reality they had experienced outcomes that were not recorded in the dataset (a form of misclassification bias).

Evidence of ICU and/or mechanical ventilation were identified via CPT/HCPCS codes as specified by the Sentinel Initiative.

Propensity score stratification was chosen as the method to balance cohorts in order to efficiently retain individuals in the analysis when handling imbalanced cohort sizes.

Several other propensity score balancing methods were considered, including 1:1 patient matching, inverse probability of treatment weighting (IPTW) with weights stabilized based on cohort size, standardized mortality ratio weighting (SMRW) with weights truncated at 8, and propensity score stratification using 500 bins.

For the individuals with COVID-19, stratified propensity weights (w_i) were calculated using the following formula:

$$w_i = \frac{n_b n_{COVID-19}}{n_{b, COVID-19} N}$$

where n_b is the number of patients in bin *b*, $n_{COVID-19}$ is the number of patients with COVID-19 in bin *b*, $n_{b, COVID-19}$ is the number of patients in bin *b* with COVID-19, and *N* is the total number of patients.

For individuals with influenza, stratified propensity weights (w_i) were calculated using the following formula:

$$w_i = \frac{n_b n_{influenza}}{n_{b, \quad influenza} N}$$

where $n_{influenza}$ is the number of patients with influenza in bin *b*, and $n_{b, influenza}$ is the number of patients in bin *b* with influenza.

For each sensitivity analysis, propensity scores were recalculated (i.e. a new regression classifier was trained on the sub-cohort included in the sensitivity analysis), and new stratified weights were computed.

To assess the impact of unmeasured confounders, an E-value was calculated for the 8 primary and secondary endpoints. This E-value determines the minimum strength an unmeasured variable would have to be associated with both the exposure (influenza vs. COVID-19) and the outcome in order for there to be no difference in the two cohorts (or, for the value of 1.0 to fall within the 95% confidence interval of the calculated hazard ratio). These results are presented in Supplemental Table 4. Analysis was performed in R version 4.1.1, using the "EValue" package [3].

Diagnosi s	ICD-10- CM	Description
COVID- 19	B9729	Other coronavirus as the cause of diseases classified elsewhere
COVID- 19	U071	COVID-19, virus identified [code effective April 1, 2020]
COVID- 19	B342	Coronavirus infection, unspecified site

Supplemental Table 1: ICD codes to define COVID-19 and influenza

COVID- 19	B9721	SARS-associated coronavirus as the cause of diseases classified elsewhere			
COVID- 19	J1281	Pneumonia due to SARS-associated coronavirus			
Influenza	J09	Influenza due to certain identified influenza viruses			
Influenza	J09X	Influenza due to identified novel influenza A virus			
Influenza	J09X1	Influenza due to identified novel influenza A virus with pneumonia			
Influenza	J09X2	Influenza due to identified novel influenza A virus with other respiratory manifestations			
Influenza	J09X3	Influenza due to identified novel influenza A virus with gastrointestinal manifestations			
Influenza	J09X9	Influenza due to identified novel influenza A virus with other manifestations			
Influenza	J10	Influenza due to other identified influenza virus			
Influenza	J100	Influenza due to other identified influenza virus with pneumonia			
Influenza	J1000	Influenza due to other identified influenza virus with unspecified type of pneumonia			
Influenza	J1001	Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia			
Influenza	J1008	Influenza due to other identified influenza virus with other specified pneumonia			
Influenza	J101	Influenza due to other identified influenza virus with other respiratory manifestations			
Influenza	J102	Influenza due to other identified influenza virus with gastrointestinal manifestations			
Influenza	J108	Influenza due to other identified influenza virus with other manifestations			
Influenza	J1081	Influenza due to other identified influenza virus with encephalopathy			
Influenza	J1082	Influenza due to other identified influenza virus with myocarditis			
Influenza	J1083	Influenza due to other identified influenza virus with otitis media			
Influenza	J1089	Influenza due to other identified influenza virus with other manifestations			
Influenza	J11	Influenza due to unidentified influenza virus			
Influenza	J110	Influenza due to unidentified influenza virus with pneumonia			
Influenza	J1100	Influenza due to unidentified influenza virus with unspecified type of pneumonia			

Influenza	J1108	Influenza due to unidentified influenza virus with specified pneumonia
Influenza	J111	Influenza due to unidentified influenza virus with other respiratory manifestations
Influenza	J112	Influenza due to unidentified influenza virus with gastrointestinal manifestations
Influenza	J118	Influenza due to unidentified influenza virus with other manifestations
Influenza	J1181	Influenza due to unidentified influenza virus with encephalopathy
Influenza	J1182	Influenza due to unidentified influenza virus with myocarditis
Influenza	J1183	Influenza due to unidentified influenza virus with otitis media
Influenza	J1189	Influenza due to unidentified influenza virus with other manifestations

Supplemental Table 2: LOINC codes used to identify SARS-COV-2 and influenza molecular tests

Diagnos is	LOINC	Description
COVID- 19	94306-8	SARS coronavirus 2 RNA panel - Unspecified specimen by NAA with probe detection
COVID- 19	94307-6	SARS coronavirus 2 N gene [Presence] in Unspecified specimen by Nucleic acid amplification using primer-probe set N1
COVID- 19	94308-4	SARS coronavirus 2 N gene [Presence] in Unspecified specimen by Nucleic acid amplification using primer-probe set N2
COVID- 19	94309-2	SARS coronavirus 2 RNA [Presence] in Unspecified specimen by NAA with probe detection
COVID- 19	94310-0	SARS-like coronavirus N gene [Presence] in Unspecified specimen by NAA with probe detection
COVID- 19	94311-8	SARS coronavirus 2 N gene [Cycle Threshold #] in Unspecified specimen by Nucleic acid amplification using primer-probe set N1
COVID- 19	94312-6	SARS coronavirus 2 N gene [Cycle Threshold #] in Unspecified specimen by Nucleic acid amplification using primer-probe set N2
COVID- 19	94313-4	SARS-like coronavirus N gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection
COVID- 19	94314-2	SARS coronavirus 2 RdRp gene [Presence] in Unspecified specimen by NAA with probe detection
COVID- 19	94315-9	SARS coronavirus 2 E gene [Presence] in Unspecified specimen by NAA with probe detection

COVID- 19	94316-7	SARS coronavirus 2 N gene [Presence] in Unspecified specimen by NAA with probe detection			
COVID- 19	94500-6	SARS coronavirus 2 RNA [Presence] in Respiratory specimen by NAA with probe detection			
COVID- 19	94502-2	SARS-related coronavirus RNA [Presence] in Respiratory specimen by NAA with probe detection			
COVID- 19	94509-7	SARS coronavirus 2 E gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection			
COVID- 19	94510-5	SARS coronavirus 2 N gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection			
COVID- 19	94511-3	SARS coronavirus 2 ORF1ab region [Cycle Threshold #] in Unspecified specimen by NAA with probe detection			
COVID- 19	94531-1	SARS coronavirus 2 RNA panel - Respiratory specimen by NAA with probe detection			
COVID- 19	94532-9	SARS-related coronavirus+MERS coronavirus RNA [Presence] in Respiratory specimen by NAA with probe detection			
COVID- 19	94533-7	SARS coronavirus 2 N gene [Presence] in Respiratory specimen by NAA with probe detection			
COVID- 19	94534-5	SARS coronavirus 2 RdRp gene [Presence] in Respiratory specimen by NAA with probe detection			
COVID- 19	94559-2	SARS coronavirus 2 ORF1ab region [Presence] in Respiratory specimen by NAA with probe detection			
COVID- 19	94565-9	SARS coronavirus 2 RNA [Presence] in Nasopharynx by NAA with non- probe detection			
COVID- 19	94639-2	SARS coronavirus 2 ORF1ab region [Presence] in Unspecified specimen by NAA with probe detection			
COVID- 19	94640-0	SARS coronavirus 2 S gene [Presence] in Respiratory specimen by NAA with probe detection			
COVID- 19	94641-8	SARS coronavirus 2 S gene [Presence] in Unspecified specimen by NAA with probe detection			
COVID- 19	94642-6	SARS coronavirus 2 S gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection			
COVID- 19	94643-4	SARS coronavirus 2 S gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection			
COVID- 19	94644-2	SARS coronavirus 2 ORF1ab region [Cycle Threshold #] in Respiratory specimen by NAA with probe detection			
COVID- 19	94645-9	SARS coronavirus 2 RdRp gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection			

COVID- 19	94646-7	SARS coronavirus 2 RdRp gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection			
COVID- 19	94647-5	SARS-related coronavirus RNA [Presence] in Unspecified specimen by NAA with probe detection			
COVID- 19	94660-8	SARS coronavirus 2 RNA [Presence] in Serum or Plasma by NAA with probe detection			
COVID- 19	94745-7	SARS coronavirus 2 RNA			
COVID- 19	94746-5	SARS coronavirus 2 RNA			
COVID- 19	94756-4	SARS coronavirus 2 N gene			
COVID- 19	94757-2	SARS coronavirus 2 N gene			
COVID- 19	94758-0	SARS-related coronavirus E gene			
COVID- 19	94759-8	SARS coronavirus 2 RNA			
COVID- 19	94760-6	SARS coronavirus 2 N gene			
COVID- 19	94765-5	SARS-related coronavirus E gene			
COVID- 19	94766-3	SARS coronavirus 2 N gene			
COVID- 19	94767-1	SARS coronavirus 2 S gene			
COVID- 19	94819-0	SARS coronavirus 2 RNA			
COVID- 19	94845-5	SARS coronavirus 2 RNA			
COVID- 19	95380-2	Influenza virus A + B and SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory specimen by NAA with probe detection			
COVID- 19	95406-5	SARS coronavirus 2 RNA			
COVID- 19	95409-9	SARS coronavirus 2 N gene			
COVID- 19	95422-2	Influenza virus A + B RNA and SARS-CoV-2 (COVID-19) N gene panel - Respiratory specimen by NAA with probe detection			

COVID- 19	95423-0	Influenza virus A + B and SARS-CoV-2 (COVID-19) identified in Respiratory specimen by NAA with probe detection			
COVID- 19	95425-5	SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by NAA with probe detection			
COVID- 19	95521-1	SARS coronavirus 2 N gene			
COVID- 19	95522-9	SARS coronavirus 2 N gene			
COVID- 19	95608-6	SARS coronavirus 2 RNA			
Influenz a	344879	Influenza virus A RNA [Presence] in Unspecified specimen by NAA with probe detection			
Influenz a	409821	Influenza virus B RNA [Presence] in Unspecified specimen by NAA with probe detection			
Influenz a	485094	Influenza virus A and B RNA [Identifier] in Unspecified specimen by NAA with probe detection			
Influenz a	502195	Respiratory pathogens DNA and RNA 12a panel - Unspecified specimen by NAA with probe detection			
Influenz a	299073	Haemophilus influenzae B DNA [Presence] in Unspecified specimen by NAA with probe detection			
Influenz a	299099	Parainfluenza virus 2 RNA [Presence] in Unspecified specimen by NAA with probe detection			
Influenz a	299107	Parainfluenza virus 3 RNA [Presence] in Unspecified specimen by NAA with probe detection			
Influenz a	299065	Haemophilus influenzae A DNA [Presence] in Unspecified specimen by NAA with probe detection			
Influenz a	299081	Parainfluenza virus 1 RNA [Presence] in Unspecified specimen by NAA with probe detection			
Influenz a	410100	Parainfluenza virus 4 RNA [Presence] in Unspecified specimen by NAA with probe detection			
Influenz a	624627	Influenza virus A+B RNA [Presence] in Unspecified specimen by NAA with probe detection			
Influenz a	821710	Parainfluenza virus 1 RNA [Presence] in Nasopharynx by NAA with non- probe detection			
Influenz a	821660	Influenza virus A RNA [Presence] in Nasopharynx by NAA with non-probe detection			
Influenz a	821728	Parainfluenza virus 2 RNA [Presence] in Nasopharynx by NAA with non- probe detection			

Influenz a	821744	Parainfluenza virus 4 RNA [Presence] in Nasopharynx by NAA with non- probe detection
Influenz a	821702	Influenza virus B RNA [Presence] in Nasopharynx by NAA with non-probe detection
Influenz a	821736	Parainfluenza virus 3 RNA [Presence] in Nasopharynx by NAA with non- probe detection
Influenz a	821678	Influenza virus A H1 RNA [Presence] in Nasopharynx by NAA with non- probe detection
Influenz a	495242	Influenza virus A H3 RNA [Presence] in Unspecified specimen by NAA with probe detection
Influenz a	495218	Influenza virus A H1 RNA [Presence] in Unspecified specimen by NAA with probe detection
Influenz a	821694	Influenza virus A H3 RNA [Presence] in Nasopharynx by NAA with non- probe detection
Influenz a	821686	Influenza virus A H1 2009 pandemic RNA [Presence] in Nasopharynx by NAA with non-probe detection
Influenz a	554659	Influenza virus A H1 2009 pandemic RNA [Presence] in Unspecified specimen by NAA with probe detection
Influenz a	554634	Influenza virus A swine origin RNA [Identifier] in Unspecified specimen by NAA with probe detection
Influenz a	760785	Influenza virus A RNA [Presence] in Nasopharynx by NAA with probe detection
Influenz a	760801	Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
Influenz a	770289	Influenza virus A H1 2009 pandemic RNA [Presence] in Nasopharynx by NAA with probe detection
Influenz a	805903	Influenza virus A H3 HA gene [Presence] in Nasopharynx by NAA with probe detection
Influenz a	770263	Influenza virus A H1 RNA [Presence] in Nasopharynx by NAA with probe detection
Influenz a	770271	Influenza virus A H3 RNA [Presence] in Nasopharynx by NAA with probe detection
Influenz a	495317	Influenza virus A RNA [Presence] in Isolate by NAA with probe detection
Influenz a	613661	Haemophilus influenzae DNA [Presence] in Unspecified specimen by NAA with probe detection
Influenz a	495358	Influenza virus B RNA [Presence] in Isolate by NAA with probe detection

Supplemental Table 3: Standardized differences of cohort characteristics before and after weighting, for the primary (full) cohort. Standardized differences for sensitivity cohorts are available on request.

		COVID-19 cohort	Influenza cohort		
I		N = 417,969 (after trimming the tails)	N = 345,934 (after trimming the tails)	Standardize d difference (before weighting)	Standardize d difference (after weighting)
	18-44	128,424 (31)	161,165 (47)	0.33	0.011
	45-54	60,179 (14)	58,547 (17)	0.07	0.006
Age	55-64	73,553 (18)	62,051 (18)	0.01	0.010
	65-74	64,416 (15)	34,519 (10)	0.16	0.010
	75-84	50,892 (12)	18,382 (5.3)	0.24	0.000
	≥85	40,505 (9.7)	11,270 (3.3)	0.26	0.015
	Male	160,795 (38)	118,043 (34)	0.09	0.007
Sex	Female	256,710 (61)	227,594 (66)	0.09	0.007
	Other/unknown	464 (0.11)	297 (0.086)	0.01	0.008
	Not hospitalized	371,878 (89)	328,280 (95)	0.22	0.079
Severity of infection <i>Time frame:</i> date of diagnosis (start of	Hospitalized, no evidence of ICU/ventilator during hospitalization	33,437 (8)	12,863 (3.7)	0.18	0.065
hospitalization) until end of hospitalization	Hospitalized with evidence of ICU/ventilator during hospitalization	12,654 (3)	4,791 (1.4)	0.11	0.041
Care setting of diagnosis	Ambulatory/outpatient	194,346 (46)	252,001 (73)	0.56	0.359

Time frame: date of diagnosis	Hospital	46,091 (11)	17,654 (5.1)	0.22	0.079
	ED	49,611 (12)	56,025 (16)	0.12	0.103
	SNF or long-term care	15,244 (3.6)	1,206 (0.35)	0.24	0.120
	Unknown/not reported	112,677 (27)	19,048 (5.5)	0.61	0.483
Recent institutional stay encounter (90 - 1 day before index)	Yes	53,607 (13)	18,001 (5.2)	0.27	0.003
Time frame: 90 - 1 day before diagnosis	No	364,362 (87)	327,933 (95)	0.27	0.003
	Anticoagulants	10,079 (2.4)	6,401 (1.9)	0.04	0.007
	Antiplatelet	18,887 (4.5)	11,397 (3.3)	0.06	0.012
	Statins	64,733 (15)	45,419 (13)	0.07	0.010
Baseline medications/transfusions	Oral chemotherapeutics	5,312 (1.3)	11,169 (3.2)	0.13	0.007
Time frame: 183 - 3 davs	Tamoxifen	2,179 (0.52)	2,166 (0.63)	0.01	0.002
before diagnosis	Oral contraceptives	4,979 (1.2)	12,088 (3.5)	0.15	0.010
	Estrogen replacement	58 (0.014)	146 (0.042)	0.02	0.002
	Testosterone replacement	522 (0.12)	1,137 (0.33)	0.04	0.003
	Cardiovascular disease	225,980 (54)	142,789 (41)	0.26	0.001
Baseline comorbidities <i>Time frame:</i>	Venous thromboembolism	14,056 (3.4)	6,614 (1.9)	0.09	0.008
365 - 1 day before diagnosis for comorbidities, 7 days before - 7 days after diagnosis for labs	Neurologic disease that promotes stasis/immobility	57,662 (14)	15,253 (4.4)	0.33	0.001
	Obesity	104,144 (25)	84,457 (24)	0.01	0.011
	Alcohol abuse	11,816 (2.8)	7,767 (2.2)	0.04	0.000

Current tobacco use	56,925 (14)	59,818 (17)	0.10	0.009
Pregnancy	14,435 (3.5)	22,349 (6.5)	0.14	0.008
Chronic kidney disease	66,574 (16)	29,906 (8.6)	0.22	0.016
cancer	35,379 (8.5)	26,486 (7.7)	0.03	0.005
COPD	54,389 (13)	40,825 (12)	0.04	0.007
diabetes	110,485 (26)	56,633 (16)	0.25	0.010
hyperlipidemia	154,459 (37)	100,661 (29)	0.17	0.009
hypertension	195,897 (47)	119,970 (35)	0.25	0.004
rheumatic disease	18,009 (4.3)	15,997 (4.6)	0.02	0.006
atrial fibrillation	32,360 (7.7)	14,331 (4.1)	0.15	0.010
antiphospholipid antibody syndrome	356 (0.085)	334 (0.097)	0.00	0.000
inherited thrombophilia	904 (0.22)	755 (0.22)	0.00	0.003
ischemic stroke	17,827 (4.3)	5,560 (1.6)	0.16	0.011
myocardial infarction	8,042 (1.9)	3,639 (1.1)	0.07	0.009
heart failure	44,876 (11)	17,687 (5.1)	0.21	0.021
peripheral arterial disease	31,758 (7.6)	9,418 (2.7)	0.22	0.010
Polycythemia (via ICD or hemoglobin >16 g/dL)	1,483 (0.35)	1,273 (0.37)	0.00	0.001
Thrombocytosis (via ICD or platelet count >450 x 10^9/L)	1,973 (0.47)	1,378 (0.4)	0.01	0.000

Supplemental Table 4: Unadjusted event rates for components of secondary composite endpoints

NOTE 1: this table should be reproduced in the three secondary analysis cohorts (inpatient diagnoses, outpatient diagnoses, NAAT diagnoses)		COVID-	19 cohort	Influenza cohort		
		Absolute risk (N, %)	Incidence rates (per person- year)	Absolute risk (N, %)	Incidence rates (per person-year)	
	Angina	1,692 (0.4)	0.03	1,353 (0.39)	0.02	
	Peripheral arterial disease	2,917 (0.7)	0.04	1,306 (0.38)	0.02	
	Amputation	1,321 (0.32)	0.02	550 (0.16)	0.01	
	Coronary angioplasty	2,760 (0.66)	0.04	2,517 (0.73)	0.03	
	Coronary artery bypass grafting	4,690 (1.1)	0.07	3,428 (0.99)	0.04	
	Venous thrombosis of devices, implants, or grafts	309 (0.074)	0.00	153 (0.044)	0.00	

Supplemental Table 5: E-values (point estimate and 95% confidence intervals) for primary and secondary outcomes. NOTE: for endpoints for which hazard ratios were not statistically significant, no E-values were calculated.

	E value, point estimate (95% CI)
Primary arterial endpoint	NA
Primary venous endpoint	2.43 (2.1)
Ischemic stroke	NA
Myocardial infarction	NA
Deep vein thrombosis	2.06 (1.67)
Pulmonary embolism	3.04 (2.52)
Secondary arterial endpoint	1.53 (1.39)

Secondary venous endpoint	
---------------------------	--

2.39 (2.06)

Supplemental Figure 1: standardized difference, visualized, for different propensity score methods (before and after balancing).

Abbreviations: IPTW - inverse probability of treatment weighting; SMRW - standardized mortality ratio weighting



Feature standardized differences for different matching methods

References

- 1. Place of Service Code Set. [cited 20 Aug 2021]. Available: https://www.cms.gov/Medicare/Coding/place-of-servicecodes/Place_of_Service_Code_Set
- 2. Dentali F, Di Micco G, Giorgi Pierfranceschi M, Gussoni G, Barillari G, Amitrano M, et al.

Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real-world clinical practice. Ann Med. 2015;47: 546–554.

3. Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Web Site and R Package for Computing E-values. Epidemiology. 2018;29: e45–e47.